Clinical Trial Update: A Real-world Study of Patients With Hidradenitis Suppurativa and High Cardiovascular Risk or Established Coronary Plaque Treated With Secukinumab

View source ↗

Summary

A real-world study evaluating outcomes in patients with hidradenitis suppurativa and high cardiovascular risk or established coronary plaque treated with secuki…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Hidradenitis Suppurativa

Drugs mentioned

• Cosentyx (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hidradenitis Suppurativa | Status: NOT_YET_RECRUITING